SCHEMBL30600510

SCHEMBL30600510

COc1ncccc1C(=O)n1nc(N)c2ccc(C3CC3)nc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.44
▸ MAPT P10636 7/20 0.41
▸ HTT P42858 6/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ TP53 P04637 2/20 0.41
▸ PKM P14618 1/20 0.41
▸ TTR P02766 1/20 0.39
▸ PIK3CA P42336 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ EGFR P00533 1/20 0.37
▸ BTK Q06187 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ CTDSP1 Q9GZU7 2/20 0.37
▸ DUSP3 P51452 1/20 0.37
▸ PTPN5 P54829 1/20 0.37
▸ PTPN11 Q06124 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ POLB P06746 3/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26675421 1.00 ELANE (0.44) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL30600507 0.87 ELANE (0.46) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL26675320 0.87 ELANE (0.46) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL29767964 0.85 ELANE (0.46) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL26675432 0.85 ALOX15 (0.48) MAPTHTTSMN1; SMN2TP53PKM
SCHEMBL26675336 0.85 ELANE (0.46) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL26675311 0.83 MAPT (0.42) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL30600513 0.83 MAPT (0.42) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL30600529 0.82 ELANE (0.44) ELANEMAPTHTTSMN1; SMN2TP53
SCHEMBL26675401 0.82 ELANE (0.44) ELANEMAPTHTTSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US claimed
CN-116867782-A Pyrazole amide derivative 豪夫迈·罗氏有限公司 2023-10-10 — — CN claimed
US-12630549-B2 Pyrazoleamide derivatives HOFFMANN-LA ROCHE INC. (US) 2026-05-19 — — US disclosed
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-11-30 — — US disclosed
CN-116867782-A Pyrazole amide derivative 豪夫迈·罗氏有限公司 2023-10-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382911-A1 PYRAZOLEAMIDE DERIVATIVES P2RY1, P2RX1, P2RX5 ELANE 1955/4885MAPT 3058/4885HTT 4269/4885
US-12630549-B2 Pyrazoleamide derivatives CYP11B2, CYP11B1, ADRA1B ELANE 2528/4885MAPT 2409/4885HTT 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback